AI assistant
Sending…
Ernexa Therapeutics Inc. — Director's Dealing 2021
Apr 5, 2021
35259_dirs_2021-04-05_fc21b2c3-3878-4846-8453-fb5c2a86c450.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Brooklyn ImmunoTherapeutics, Inc. (BTX)
CIK: 0000748592
Period of Report: 2021-03-25
Reporting Person: Greenwood Luba (N/A)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 50032 | Direct |
More from Ernexa Therapeutics Inc.
Major Shareholding Notification
2026
May 14
Annual Report
2026
May 11
Proxy Solicitation & Information Statement
2026
May 11
Proxy Solicitation & Information Statement
2026
May 11
Interim / Quarterly Report
2026
May 11
Regulatory Filings
2026
May 4
Regulatory Filings
2026
Apr 13
Regulatory Filings
2026
Apr 1
Regulatory Filings
2026
Mar 31
Regulatory Filings
2026
Mar 24